PD-1^hiCXCR5⁻CD4⁺T Peripheral Helper Cells Were Enriched and Potentially Predicted Clinical Response to Etanercept Therapy in Rheumatoid Arthritis

Abstract

Rheumatoid arthritis (RA) remains a challenging autoimmune disease with variable treatment responses to tumor necrosis factor-α (TNF-α) inhibitors. This study investigates the clinical significance of PD-1^hiCXCR5⁻CD4⁺T peripheral helper (Tph) cells in RA and their potential utility as biomarkers for predicting etanercept (ETN) therapy response. We enrolled 58 RA patients, 12 age- and sex-matched osteoarthritis patients, and 15 healthy controls, with Tph cells quantified by flow cytometry. Among 25 RA patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs receiving ETN therapy, treatment outcomes were stratified by ACR20 response criteria. Tph cell frequency was significantly elevated in RA patients and correlated positively with multiple disease activity indicators. At baseline, ETN nonresponders exhibited higher Tph proportions than responders (13.23 ± 2.60% vs. 10.82 ± 3.08%, p = 0.0467). Following ETN treatment, responders demonstrated significant Tph reduction (10.82% decreased to 7.97%, p = 0.0105), paralleling serum IL-21 dynamics. In an exploratory analysis, baseline Tph levels showed an association with ETN response. These findings suggest that circulating Tph cells may serve as a candidate biomarker for RA disease activity and therapeutic response monitoring, warranting further validation in larger prospective cohorts.

Keywords

disease activity / efficacy prediction / rheumatoid arthritis / TNF-α inhibitor / T peripheral helper cell

References

[1] A. Di Matteo, J. M. Bathon, and P. Emery, “Rheumatoid Arthritis,” Lancet 402, no. 10416 (2023): 2019–2033.

[2] D. P. Misra, “Clinical Manifestations of Rheumatoid Arthritis, Including Comorbidities, Complications, and Long-Term Follow-Up,” Best Practice & Research Clinical Rheumatology 39, no. 1 (2025): 102020.

[3] Y. Zhu, H. Xu, L. Zhang, et al., “Biopsychosocial Determinants and Gender Disparities in Health-Related Quality of Life Among Rheumatoid Arthritis Patients: A Nationwide Multicentre Study in China,” Clinical and Experimental Rheumatology (2026), Published online February 20, 2026.

[4] Y. Zhou, X. Wang, Y. An, et al., “Disability and Health-Related Quality of Life in Chinese Patients With Rheumatoid Arthritis: A Cross-Sectional Study,” International Journal of Rheumatic Diseases 21, no. 9 (2018): 1709–1715.

[5] J. S. Smolen, C. J. Edwards, V. Konzett, et al., “EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Antirheumatic Drugs: 2025 Update,” Annals of the Rheumatic Diseases 85, no. 6 (2026): 991–1009.

[6] J. S. Smolen, D. Aletaha, A. Barton, et al., “Rheumatoid Arthritis,” Nature Reviews Disease Primers 4 (2018): 18001.

[7] G. Nagy, N. M. T. Roodenrijs, P. M. J. Welsing, et al., “EULAR Points to Consider for the Management of Difficult-to-Treat Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 81, no. 1 (2021): 20–33.

[8] E. M. Gravallese and G. S. Firestein, “Rheumatoid Arthritis—Common Origins, Divergent Mechanisms,” New England Journal of Medicine 388, no. 6 (2023): 529–542.

[9] P. Yang, F.-Y. Qian, M.-F. Zhang, et al., “Th17 Cell Pathogenicity and Plasticity in Rheumatoid Arthritis,” Journal of Leukocyte Biology 106, no. 6 (2019): 1233–1240.

[10] Q. Niu, B. Cai, Z. Huang, Y. Shi, and L. Wang, “Disturbed Th17/Treg Balance in Patients With Rheumatoid Arthritis,” Rheumatology International 32, no. 9 (2012): 2731–2736.

[11] L. Zheng, M. Gu, X. Li, et al., “ITGA5+ Synovial Fibroblasts Orchestrate Proinflammatory Niche Formation by Remodelling the Local Immune Microenvironment in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 84, no. 2 (2025): 232–252.

[12] C. Xiao, Z. Su, J. Zhao, et al., “Novel Regulation Mechanism of Histone Methyltransferase SMYD5 in Rheumatoid Arthritis,” Cellular & Molecular Biology Letters 30, no. 1 (2025): 38.

[13] F. Zhang, K. Wei, K. Slowikowski, et al., “Defining Inflammatory Cell States in Rheumatoid Arthritis Joint Synovial Tissues by Integrating Single-Cell Transcriptomics and Mass Cytometry,” Nature Immunology 20, no. 7 (2019): 928–942.

[14] D. A. Rao, M. F. Gurish, J. L. Marshall, et al., “Pathologically Expanded Peripheral T Helper Cell Subset Drives B Cells in Rheumatoid Arthritis,” Nature 542, no. 7639 (2017): 110–114.

[15] A. V. Bocharnikov, J. Keegan, V. S. Wacleche, et al., “PD-1hiCXCR5- T Peripheral Helper Cells Promote B Cell Responses in Lupus via MAF and IL-21,” JCI Insight 4, no. 20 (2019): e130062.

[16] Y. Masuo, A. Murakami, R. Akamine, et al., “Stem-Like and Effector Peripheral Helper T Cells Comprise Distinct Subsets in Rheumatoid Arthritis,” Science Immunology 10, no. 110 (2025): eadt3955.

[17] J. Sowerby, J. Choi, and D. A. Rao, “T Peripheral Helper Cells in Lymphoid Aggregate and Tertiary Lymphoid Structure Formation,” Immunological Reviews 337, no. 1 (2026): e70088.

[18] A. Argyriou, M. H. Wadsworth, A. Lendvai, et al., “Single Cell Sequencing Identifies Clonally Expanded Synovial CD4+ TPH Cells Expressing GPR56 in Rheumatoid Arthritis,” Nature Communications 13, no. 1 (2022): 4046.

[19] E. Yokoi, K. Wakahara, S. Nakamura, et al., “Increased Sputum Peripheral Helper T Cells Are Associated With the Severity of Rheumatoid Arthritis but Not With the Severity of Airway Disease,” Frontiers in Immunology 16 (2025): 1526881.

[20] L. Garrison and N. D. McDonnell, “Etanercept: Therapeutic Use in Patients With Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 58, no. 1 (1999): I65–I69.

[21] T. Fan, C. Tai, K. C. Sleiman, et al., “Aberrant T Follicular Helper Cells Generated by TH17 Cell Plasticity in the Gut Promote Extraintestinal Autoimmunity,” Nature Immunology 26, no. 5 (2025): 790–804.

[22] J. Lu, J. Wu, X. Xia, H. Peng, and S. Wang, “Follicular Helper T Cells: Potential Therapeutic Targets in Rheumatoid Arthritis,” Cellular and Molecular Life Sciences 78, no. 12 (2021): 5095–5106.

[23] S. Crotty, “Follicular Helper CD4 T Cells (TFH),” Annual Review of Immunology 29 (2011): 621–663.

[24] J. L. Cannons, H. Qi, K. Lu, et al., “Optimal Germinal Center Responses Require a Multistage T Cell:B Cell Adhesion Process Involving Integrins, SLAM-Associated Protein, and CD84,” Immunity 32, no. 2 (2010): 253–265.

[25] S. Pan, X. Xiao, T. Li, et al., “Definition of Follicular Helper T Cell and Cytokines Expression in Synovial Fluid of Rheumatoid Arthritis,” Clinical Rheumatology 43, no. 1 (2024): 129–135.

[26] X. Hou, C. Yang, M. Lin, et al., “Altered Peripheral Helper T Cells in Peripheral Blood and Muscle Tissue of the Patients With Dermatomyositis,” Clinical and Experimental Medicine 21, no. 4 (2021): 655–661.

[27] P. Fortea-Gordo, L. Nuño, A. Villalba, et al., “Two Populations of Circulating PD-1hiCD4 T Cells With Distinct B Cell Helping Capacity Are Elevated in Early Rheumatoid Arthritis,” Rheumatology 58, no. 9 (2019): 1662–1673.

[28] X. Wei and X. Niu, “T Follicular Helper Cells in Autoimmune Diseases,” Journal of Autoimmunity 134 (2022): 102976.

[29] M. Akiyama, W. Alshehri, K. Yoshimoto, and Y. Kaneko, “T Follicular Helper Cells and T Peripheral Helper Cells in Rheumatic and Musculoskeletal Diseases,” Annals of the Rheumatic Diseases 82, no. 11 (2023): 1371–1381.

[30] A. Julià, G. Ávila, R. Celis, et al., “Lower Peripheral Helper T Cell Levels in the Synovium Are Associated With a Better Response to Anti-TNF Therapy in Rheumatoid Arthritis,” Arthritis Research & Therapy 22, no. 1 (2020): 196.

[31] D. Aletaha, T. Neogi, A. J. Silman, et al., “2010 Rheumatoid Arthritis Classification Criteria: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative,” Arthritis and Rheumatism 62, no. 9 (2010): 2569–2581.

[32] J. Anderson, L. Caplan, J. Yazdany, et al., “Rheumatoid Arthritis Disease Activity Measures: American College of Rheumatology Recommendations for Use in Clinical Practice,” Arthritis Care & Research 64, no. 5 (2012): 640–647.

[33] D. T. Felson, J. J. Anderson, M. Boers, et al., “American College of Rheumatology Preliminary Definition of Improvement in Rheumatoid Arthritis,” Arthritis & Rheumatism 38, no. 6 (1995): 727–735.

[34] V. Konzett, A. Kerschbaumer, J. S. Smolen, and D. Aletaha, “Determination of the Most Appropriate ACR Response Definition for Contemporary Drug Approval Trials in Rheumatoid Arthritis,” Annals of the Rheumatic Diseases 83, no. 1 (2024): 58–64.

Rights & permissions

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.